PPBT News and Press, Purple Biotech Ltd.

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X (SOXS) fell 24.4% to $4.97 on volume of 883,191,047 shares Aditxt Inc. (ADTX) fell 29.7% to $0.013 on volume of 595,606,788 shares Direxion Small Cap Bear 3X (TZA) fell 8.8% to $4.27 on volume of 333...

A look at the top 10 most actives in the United States Aditxt Inc. (ADTX) fell 17.3% to $0.015301 on volume of 378,944,670 shares Direxion Daily Semiconductor Bear 3X (SOXS) fell 10.4% to $5.89 on volume of 164,597,491 shares Theriva Biologics, Inc. (TOVX) rose 75.7% to $0.427801 on volume ...

Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safety profile compared to the non-capped variant IM1240 demonstrated anti-tumor activity across ...

2026-05-15 07:08:29 ET More on Purple Biotech Purple Biotech Non-GAAP EPS of $19.85 Seeking Alpha’s Quant Rating on Purple Biotech Historical earnings data for Purple Biotech Financial information for Purple Biotech Read the full article on S...

New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biolog...

Issued on behalf of GT Biopharma, Inc. Key Takeaways - First patient dosed in Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager — the third TriKE® program to enter clinical testing. - Dose-escalation phase will focus primarily ...

Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded to IM1240 treatment New data shows that the NKG2A arm significantly enhanced anti-tumor activ...

Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3’s advancement toward clinical-stage immunotherapy development SAB leverages expertise in translational science, NK and T cell biology REHOVOT, Israel an...

Collaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needs AI-driven development strategy designed to significantly accelerate discovery timelines and enhance molecule quality for drug candidates targeting solid tum...

2026-03-17 07:19:39 ET More on Purple Biotech Purple Biotech Non-GAAP EPS of $19.85 Seeking Alpha’s Quant Rating on Purple Biotech Historical earnings data for Purple Biotech Financial information for Purple Biotech Read the full article on S...